Influenza A viruses are a major cause of mortality. Given the potential for future lethal pandemics, effective drugs are needed for the treatment of severe influenza such as that caused by H5N1 viruses. Using mediator lipidomics and bioactive lipid screen, we report that the omega-3 polyunsaturated fatty acid (PUFA)-derived lipid mediator protectin D1 (PD1) markedly attenuated influenza virus replication via RNA export machinery. Production of PD1 was suppressed during severe influenza and PD1 levels inversely correlated with the pathogenicity of H5N1 viruses. Suppression of PD1 was genetically mapped to 12/15-lipoxygenase activity. Importantly, PD1 treatment improved the survival and pathology of severe influenza in mice, even under conditions where known antiviral drugs fail to protect from death. These results identify the endogenous lipid mediator PD1 as an innate suppressor of influenza virus replication that protects against lethal influenza virus infection.
INTRODUCTION
Despite immunization programs, influenza A viruses are a major cause of morbidity and mortality throughout the world, especially among individuals with high risk factors, such as diabetes, asthma, or pregnancy (Clark and Lynch, 2011) . Highly pathogenic avian H5N1 influenza viruses continue to circulate with mortality rates of up to 60% of infected patients (Beigel et al., 2005) . Influenza strains have also recently emerged that exhibit resistance to antiviral drugs such as oseltamivir (Shankaran and Bearman, 2012) . Recently, a virus with its hemagglutinin (HA) derived from H5N1 was identified that is transmissible in ferrets, further supporting that H5N1 viruses have pandemic potential (Imai and Kawaoka, 2012) . Moreover, currently used antiviral drugs, though beneficial if administered early in the disease (Kumar, 2011) , are not effective in critically ill patients after influenza virus infections (Beigel et al., 2005; Clark and Lynch, 2011; Kumar et al., 2010) .
Influenza A viruses are negative-sense RNA viruses that exploit the host cellular machinery for multiple phases of their life cycle (Neumann et al., 2004) . Recent genome-wide RNAi screens have identified several host genes and molecular networks crucial for influenza virus replication (Karlas et However, whether bioactive lipid mediators and lipid metabolic pathways might be involved in influenza virus infections is unknown. Omega-3 polyunsaturated fatty acids (PUFA), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), both of which are enriched in fish oils, serve as substrates for the production of potent bioactive anti-inflammatory lipid mediators, such as resolvins, protectins, maresins, and their biosynthetic intermediates (Serhan, 2007; Serhan et al., 2012) .
Here, we report that the DHA-derived protectin D1 isomer (PD1; 10S, 17S-dihydroxydocosahexaenoic acid) markedly attenuates influenza virus replication via interference with the virus RNA nuclear export machinery. PD1 was identified in self-limited resolving inflammatory exudates in vivo (Serhan et al., 2002) , where it regulates the innate local response and stimulates resolution. Production of PD1 was downregulated during severe influenza virus infections, e.g., with H5N1 avian influenza viruses, and inversely correlated with the pathogenicity of different H5N1 virus isolates. Importantly, PD1 treatment improved the survival of influenza-virus-infected mice even at later stages of the disease, when current antiviral therapies are not effective (Arya et al., 2010) , suggesting that PD1 could be a novel therapeutic target for the treatment of severe influenza virus infections.
RESULTS
The PUFA-Derived Mediator Protectin D1 Reduces Influenza Virus Replication To investigate the potential role of lipid metabolites in influenza infections, we performed a screen of PUFA-derived lipids in human lung epithelial (A549) cells infected with the influenza A virus stain A/Puerto Rico/8/34 (H1N1) (PR8 virus) by using bioactive lipid libraries that include prostaglandins (PGs), resolvins, protectins, and other PUFA-derived metabolites ( Figure 1A ). PR8-infected cells (multiplicity of infection [MOI] : 0.2) were treated with PUFA-derived metabolites (1 mM each) and influenza virus nucleoprotein (NP) mRNA expression was quantified at 8 hr after infection ( Figure 1A ). Compared with vehicle treatment, the arachidonic acid (AA)-derived products 12-HETE and 15-HETE, as well as the DHA-derived 17HDoHE and PD1, inhibited the expression of NP mRNA by more than 30%. Of note, some compounds, e.g., 8,9-DHET, resulted in increased NP mRNA levels that required further analysis; here, we focus on compounds that can inhibit virus replication because they may represent potential therapeutic targets for influenza virus infection. Immunohistochemistry demonstrated that PD1, 17-HDoHE, 12-HETE, and 15-HETE administration markedly decreased the numbers of cells that were positive for the influenza virus NP protein and viral antigen R309 ( Figure 1B ). In addition, PR8 virus titers were markedly decreased by the treatment with 12-HETE, 15-HETE, 17HDoHE, and PD1 ( Figure 1C) . Consistent with the results of our screen, the DHA-derived resolvins RvD1 and RvD2 showed no apparent inhibition (Figures 1B and 1C) . Because PD1 treatment among all bioactive mediators tested led to the most potent inhibition of PR8 virus replication, we focused on PD1 for our subsequent studies. We confirmed that PD1 treatment attenuated influenza virus replication, as assessed by NP protein production in PR8-virus-infected A549 cells ( Figure S1A available online). NP mRNA expression was inhibited by PD1 treatment in a dose-dependent fashion (Figure S1B) . Importantly, PD1 treatment also attenuated the replication of highly pathogenic H5N1 influenza viruses, as assessed by markedly reduced viral M protein mRNA expression ( Figures 1D and S1C ), and decreased virus titers (Figures 1E and S1D) in A549 and MDCK cells. Thus, our screen for PUFAderived metabolites identified PD1 as a suppressor of influenza virus replication in cultured cells.
Reduction of Endogenous PD1 Production in Lungs of Mice in Severe Influenza Virus Infection
To examine the metabolic profiles of PUFA-derived metabolites in severe influenza infection in vivo, we conducted a mediator lipidomics for AA-, DHA-and EPA-derived metabolites in lung tissues obtained from wild-type mice subjected to intratracheal PR8-virus infections (Ichikawa et al., 2013) . All PR8-infected animals died within 8 days ( Figure S2A ). NP mRNA expression ( Figure S2B ) and virus titers ( Figure S2C ) rapidly increased after infection peaking on day 2. PR8 infections also resulted in markedly impaired pulmonary functions as assessed by tissue resistance and tissue elastance ( Figure S2D ) (Sly et al., 2003) . Histologically, numbers of inflammatory cells were slightly increased in the PR8-infected lungs on day 2, and on day 5 we observed pulmonary edema, hemorrhage, and hyaline membrane formation ( Figure S2E ). Thus, in line with previous reports (Smith et al., 2011; Ichikawa et al., 2013) , intratracheal infection with PR8 influenza viruses induces lung pathologies that closely mimic the symptoms of severe influenza in humans.
To identify the endogenous lipid mediators and pathway metabolites during PR8 infections, lung tissues were obtained from PR8-and mock-infected mice at 6, 12, 24, and 48 hr after infection and subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based lipidomics analysis. This technology has been recently developed and allows researchers to identify and quantify more than 250 PUFAderived endogenous lipid mediators and pathway metabolites including prostaglandins (PGs), leukotrienes (LTs), lipoxins (LXs), resolvins, protectins, and other AA-, EPA-, DHA-derived products (Arita, 2012) . As shown in Tables S1, S2 , and S3, several lipid mediators were detectable in noninfected lungs under baseline control conditions. In particular, cyclooxygenase (COX) pathway products such as PGE2 and 6-keto PGF1a and the 12/15-lipoxygenase (12/15-LOX) pathway metabolites 12-HETE, 15-HETE, and 14-HDoHE were present in the lung tissues of untreated control mice (Tables S1 and S2 ). Next, we examined the relative ratios of AA-derived (Figure 2A ), DHA-derived (Figure 2B) , and EPA-derived ( Figure 2C ) metabolites in PR8-infected versus control lungs. Intriguingly, among all the identified mediators and metabolites, endogenous production of AAderived 12-HETE and 15-HETE, as well as DHA-derived 17-HDoHE and PD1, showed the greatest level of reduction during the course of the PR8 influenza virus infection ( Figures 2A-2C) ; these are the same series of lipid mediators that showed the largest impact on influenza replication in A549 cells (Figure 1 ). Akin to its effects on viral replication in cell culture, PD1 was one of the most reduced lipid mediator in the lungs of PR8-infected mice ( Figure 2B) . (legend continued on next page)
To extend our results to other influenza virus strains, we intranasally (i.n.) infected wild-type mice with 2009 H1N1 virus, avian H5N1 (H5N1) virus, avian H5N1 virus carrying an attenuating Glu mutation at position 627 of PB2 (H5N1 PB2-627E), or mock infected them. Virus titers were higher in the lungs of mice infected with the avian H5N1 virus as compared to 2009 H1N1 or H5N1-PB2-627E-virus-infected mice ( Figure S2F ), confirming previous results (Shinya et al., 2004) . Lung tissues were obtained at 24 and 48 hr after infection and subjected to LC-MS/MS-based lipidomics analysis. Again, endogenous production of AA-derived 12-HETE and 15-HETE, and of DHA-derived 17-HDoHE and PD1, was markedly downregulated in lungs infected with the highly pathogenic avian H5N1 virus at both time points analyzed (Figure 3 ). PD1 production was the most suppressed in H5N1-virus-infected lungs, whereas it was even elevated in lungs infected with the less pathogenic 2009 H1N1 virus and H5N1 PB2-627E virus strains (Figure 3 ), suggesting that endogenous PD1 levels inversely correlate with the pathogenicity of influenza virus strains. Taken together, our data show that endogenous production of PD1 is markedly suppressed in the lungs of mice intratracheally infected with PR8 virus or nasally infected with the highly pathogenic avian H5N1 influenza virus.
PD1 Protects against Severe Influenza In Vivo
We next tested whether the PUFA-derived 12-HETE, 15-HETE, 17-HDoHE, and PD1, all of which attenuated virus replication in cultured cells (Figure 1 ), could also protect against severe influenza in mice. Mice were infected intratracheally with PR8 virus (1,500 TCID 50 ); lipids mediators (1 mg/mouse) or vehicle were given intravenously (i.v.) 12 hr before and immediately after the PR8 virus infection. The lipids metabolites were given intravenously because they are autacoids and, as such, are rapidly metabolized and inactivated in vivo. Consistent with our in vitro data, PD1 treatment improved the survival of PR8-infected mice ( Figure 4A ). To extend our results to a human pathogenic virus isolate, we tested whether PD1 treatment could also affect the survival of mice infected with the 2009 H1N1 virus. When PD1 was given i.v. 12 hr before and immediately after 2009 H1N1 virus infections, the survival of the virus-infected mice improved ( Figure 4B ). We then tested whether the protective actions of PD1 resulted from its anti-inflammatory functions in macrophages and neutrophils (Schwab et al., 2007) . However, macrophage and neutrophil numbers in bronchioalveolar lavage (BAL) fluid were seemingly unaffected by PD1 treatment in the lungs of PR8 influenza-virus-infected mice ( Figure S3A ), although the PD1-treated lungs did show slightly improved histological changes at 2 days after infection ( Figure S3B ). Furthermore, PD1 treatment did not significantly decrease the levels of the proinflammatory cytokines IL-6, IP-10, and CXCL2 nor mRNA expression (IL-6, IFN-b, CXCL1, and CXCL2) in the lungs on days 2 and 5 after PR8 infection ( Figures 4C and S3C ). In contrast, virus NP mRNA expression ( Figure 4D ), virus titers (Figure 4E) , and the number of virus antigen-positive cells ( Figure 4F ) were all significantly reduced in the lungs of PD1-treated mice, indicating that PD1 acts on viral replication.
Similar to our in vitro data (Figure 1 ), intravenous treatment (1 mg/mouse) with RvD1 or RvD2 at 12 hr before and immediately after PR8 virus infection had no apparent effect on the survival of PR8-virus-infected mice ( Figure 4G ). Because LXA4 showed a mild inhibition of virus replication ( Figure 1 ) and LXA4 production was suppressed during the course of severe influenza (Figure 2A) , we also tested the effect of LXA4 on the survival of mice infected with PR8 influenza virus in vivo. However, treatment (1 mg/mouse, i.v.) with LXA4 also had no apparent effect on the survival of PR8-virus-infected mice ( Figure 4G ). Given that RvD1, RvD2, and LXA4 are known to have anti-inflammatory properties (Serhan and Levy, 2003) , we next asked whether they could decrease the inflammatory cytokine production initiated in response to virus infection. However, RvD1, RvD2, or LXA4 treatment did not decrease the proinflammatory cytokine levels (IL-6, IP-10, CXCL2) in the lungs on days 2 and 5 after PR8 infection ( Figure S3D ). In addition, virus replication, as assessed by NP mRNA, was apparently not affected following treatment with these lipid metabolites ( Figure 4H ).
We finally examined whether PD1 treatment has a therapeutic benefit after the infection was established. Mice were infected i.t. with PR8 virus and treated with PD1 (100 ng/mouse; i.t.) or vehicle 2 days after the initial infection; infected mice were then mechanically ventilated, mimicking the therapeutic setting for critically ill influenza patients in intensive care units. We chose the 48 hr time point because currently available anti-influenza drugs are thought to be beneficial if administered early after infection but ineffective if administered around 48 hr after infection (Kumar, 2011) . Intriguingly, such therapeutic PD1 treatment significantly improved the pulmonary functions of PR8-infected mice as assessed by tissue resistance ( Figure 4I ) and tissue elastance ( Figure 4J ). A similar administration regiment using RvD1 or RvD2 did not improve pulmonary functions (Figures S3E and S3F) . Importantly, when mice were treated with the antiviral drug peramivir (Arya et al., 2010) or PD1 alone at 48 hr postinfection, 70%-75% of the animals still died within 16 days ( Figure 4K ). However, PD1 plus peramivir treatment beginning 48 hr after infection completely rescued the mice from death due to the influenza infection ( Figure 4K ). Of note, if treated with peramivir immediately after infection, all animals survived ( Figure S3G ). These results show that PD1 has a marked beneficial effect on severe influenza virus infections both prophylactically and, most importantly, therapeutically in vivo.
PD1 Inhibits Nuclear Export of Viral Transcripts
Next, we explore the mechanisms by which PD1 inhibits influenza virus replication. Consistent with our in vivo data ( Figures viral ribonucleoprotein (vRNP) complexes. vRNA is replicated into cRNA, which serves as the template for vRNA neosynthesis. After the formation of vRNPs in the nucleus, vRNAs are exported to the cytoplasm (Neumann et al., 2004) . In addition, an initial round of transcription produces 5 0 capped and 3 0 poly(A) viral mRNA that is also exported to the cytoplasm. To examine whether PD1 affects the nuclear export of influenza virus RNA, we visualized the localization of PR8 virus segment 7 mRNA and vRNA in infected A549 cells using fluorescence in situ hybridization (FISH). Upon PR8 virus infection, virus mRNA and vRNA were primarily localized in the nucleus at 5 hr after infection but shifted to the cytoplasm at 8 hr in the vehicle-treated cells ( Figure 5A translocation of virus mRNA and vRNA ( Figure 5A ). Of note, RvD1 treatment did not affect the export of viral RNAs (Figure 5A) . As a consequence, virus mRNA and vRNA expression was significantly reduced in the PD1-treated but not RvD1-treated cytoplasmic fraction 8 hr after PR8 infections ( Figure 5B ). Thus, our data indicate that PD1 inhibits nuclear export of influenza virus RNAs. Genome-wide RNAi screens for host factors implicated in influenza virus replication identified a critical role for the mRNA transporter NXF1 (also known as Tap) (Karlas et al., 2010; Hao et al., 2008) , although the precise mechanisms remained unknown. We therefore assessed a potential involvement of NXF1 in the PD1-regulated nuclear export of influenza virus RNA. Indeed, knockdown of NXF1 in A549 cells ( Figure S4B ), but not of the related transporters p15/NXT1 (Herold et al., 2001) , NXT2, or CRM1/ XPO1 (Stade et al., 1997) , significantly attenuated PR8 influenza virus replication as assessed by NP mRNA expression ( Figure 5C ), NP protein levels (Figure S4C) , and virus titers ( Figure S4D ). Consistent with a previous report (Read and Digard, 2010) , FISH analyses further confirmed that knockdown of NXF1 inhibited the nuclear export of virus mRNA and vRNA ( Figure S4E ). Of note, although knockdown of p15/NXT1 or its homolog NXT2 (Herold et al., 2000) alone did not attenuate virus replication, knockdown of both p15/NXT1 and NXT2 attenuated the influenza virus replication ( Figure 5C ). Knockdown of CRM1/XPO1 did not affect the nuclear export of influenza virus transcripts ( Figure S4F ). NXF1 forms a functional heterodimer with the p15/NXT1 protein (Grü ter et al., 1998; Herold et al., 2000; Katahira et al., 1999; Rodríguez-Navarro and Hurt, 2011) . NXF1 proteins, via their middle (M) and C-terminal domains (Figure S4G ), bind to phenylalanine-glycine (FG) repeat-containing nucleoporins (Nups) that line the nuclear pore channel (Ho . FG-Nups facilitate RNA transport as their repeats provide docking sites for carriers during their movement across the nuclear pore complex (Reed and Hurt, 2002; Stewart, 2010) . Among FG-Nups, knockdown of Nup62, but not Nup98 or Nup214, significantly attenuated virus replication assessed by NP mRNA expression ( Figure 5D ) and virus titers ( Figure S5A ) in A549 cells, as previously reported for immunodeficiency virus type 1 (HIV-1) infections (Monette et al., 2011) . FISH analyses further showed that Nup62 knockdown inhibited the nuclear export of virus mRNA and vRNA ( Figure S5B ), whereas knockdown of Nup98 nor Nup214 did not affect the nuclear export of influenza virus transcripts ( Figure S5C ). Whether influenza virus RNAs can directly bind NXF1 has been elusive. By using a cell-free in vitro RNA gel shift assay, we found that recombinant protein expressing full-length NXF1 1-619 and p15/NXT1 (NXF1-p15) generated band shifts of influenza virus mRNA and vRNA ( Figure S6A ), indicating that influenza virus RNAs directly binds to NXF1-p15. In contrast, we failed to detect a direct binding of Nup62-FG protein to virus RNAs ( Figure S6B ). Interestingly, coincubation of the NXF1-p15 and Nup62-FG proteins generated a supershift of influenza virus mRNA and vRNA ( Figure 5E ), supporting the notion that NXF1-p15 and Nup62-FG form a protein complex in vitro, which can bind virus RNAs. Of note, immunoprecipitation experiments showed that Nup62 indeed associated with NXF1 in noninfected and infected cells ( Figure S6C ). These data indicate that influenza virus RNAs directly bind to NXF1 and that NXF1, in cooperating with a key docking protein Nup62, facilitates influenza virus RNAs export and virus replication. We next tested whether PD1 could interfere with the recruitment of virus RNAs to NXF1 that can bind Nup62 using an RNA immunoprecipitation (RIP) assays. PD1, but not RvD1, treatment significantly reduced the amount of virus mRNA and vRNA that immunoprecipitated with the anti-NXF1 antibody (Ab) ( Figure 5F ). The Ab used was immunoprecipitated with NXF1 ( Figure S6D ). To further confirm this finding, we conducted a RIP sequencing (RIPseq) analysis. The RNAs that immunoprecipitated with the anti-NXF1 Ab indeed mapped to influenza virus RNAs. PD1 treatment significantly reduced the copy number of all influenza virus RNAs that immunoprecipitated with the anti-NXF1 Ab ( Figure 5G ). Furthermore, we detected the presence of Nup62 microclusters around the nuclear rim and a distinct speckled cytoplasmic staining at 8 hr after infection ( Figure 5H ). Importantly, upon PD1, but not RvD1, treatment, Nup62 remained at the nuclear envelop in the virus-infected cells (Figure 5H) . Taken together, our data indicate that PD1 inhibits the recruitment of virus RNAs to NXF1 that can cooperate with Nup62 for RNA export, thereby attenuating virus RNA export and replication.
Finally, we asked whether PD1 also affects nuclear export of host poly(A) mRNA. FISH analysis showed that PD1 treatment had no apparent impact on the nuclear export of host bulk poly(A) mRNA in the influenza-virus-infected cells ( Figure 5I ). To confirm this finding, we isolated nuclear and cytoplasmic RNA fractions from the cells at 8 hr after mock or PR8 virus infection and subjected to RNA sequencing (RNAseq) analysis. Consistent with our FISH data ( Figure 5I ), the distributions of nuclear and cytoplasmic RNA sequences were largely unaffected by PD1 treatment (Figure 5J ), although some RNAs appeared changed following PD1 treatment (Table S4) ; the significance of these changes needs to be determined, though none of these changed RNA have been yet implicated in virus replication.
PD1 Production Is 12/15-LOX Dependent 12/15-LOX (the murine ortholog of human 15-LOX1) (Chanez et al., 2002 ) is known to be a key enzyme in the biosynthesis of PD1 (Yamada et al., 2011) . To test whether the generation of PD1 in the influenza-virus-infected lung was indeed dependent on 12/15-LOX, we conducted lipidomics for PUFA-derived metabolites in 12/15-LOX knockout (KO) (Sun and Funk, 1996) versus control wild-type (WT) mice. Compared with WT mice, levels of PD1 were reduced in 12/15 LOX KO mice at baseline ( Figure 6A ). Upon influenza virus infection for 24 hr, production of PD1 was markedly reduced in 12/15 LOX KO mice ( Figure 6A ). In addition, the production of 17-HDoHE, the upstream product of PD1, was also markedly reduced in 12/15 LOX KO mice at baseline and at 24 hr postinfection ( Figure 6A ). Of note, production of LXA 4 was apparently not affected by the genetic inactivation of 12/15-LOX ( Figure S7A ). 5-lipoxygenase followed by 12-lipoxygenase action (Papayianni et al., 1995) might be involved in the production of lipoxin A4. These data indicate that the endogenous production of PD1 is critically dependent on 12/15-LOX expression.
In lungs, 12/15-LOX is predominantly expressed in epithelial cells and leukocytes (Chanez et al., 2002) . In PR8-infected mice, mRNA ( Figure 6B ) and protein levels ( Figure 6C ) of 12/ 15-LOX were decreased in lungs. NP mRNA levels ( Figure 6D ) and virus titers ( Figure 6E ) were significantly higher in the lung tissues of PR8-virus-infected 12/15-LOX deficient mice at 2 days postinfection. 12/15-LOX KO mice also exhibited greater body weight loss after PR8 virus infections ( Figure 6F) . Furthermore, we isolated mouse embryonic fibroblasts (MEFs) from WT and 12/15-LOX KO mice and infected them with the PR8 (G and H) RvD1, RvD2, LXA4, or vehicle was given i.v. 12 hr before and immediately after PR8 infection of WT mice (n = 6 for each group). Percent survival is shown (G). NP mRNA expression was measured in lungs at 2 and 5 days postinfection (H). (I and J) Therapeutic effects of PD1 on lung function of PR8-infected mice. Two days postinfection mice were intratracheally treated with PD1 or vehicle (veh), and then mechanically ventilated for 2.5 hr. Changes in pulmonary tissue resistance (I) and tissue elastance (J) were analyzed. n = 6 per group. **p < 0.01 for the entire time course compared with vehicle treatment. (K) Survival of influenza-virus-infected mice upon delayed treatment with the antiviral drug peramivir (n = 5), PD1 (n = 7), peramivir plus PD1 (n = 7), or vehicle (n = 7). WT mice were infected intratracheally with PR8 virus. In the peramivir group, 2 days postinfection, peramivir (10 mg/kg) was given i.v. In the PD1 group, from 2 days postinfection PD1 (1 mg/mouse/day) was given i.v. for 3 consecutive days. In the peramivir plus PD1 group, peramivir (10 mg/kg) was given i.v. at 2 days postinfection and PD1 (1 mg/mouse/day) was given i.v. for three consecutive days as indicated. Data in (C), (D), (E), and (H)-(J) are presented as means ± S.E.M. See also Figure S3 . (legend continued on next page)
viruses. NP mRNA levels ( Figure 6G ) and virus titers ( Figure S7C ) were again markedly higher in 12/15-LOX KO MEFs. Importantly, the elevated NP mRNA expression ( Figure 6G ) and virus titers ( Figure S7C ) in the 12/15-LOX KO MEFs were significantly attenuated by the treatment with PD1, 17-HDoHE, or a combination of both. These results show that the 12/15-LOX is the key enzyme required for the biosynthesis of PD1 and 17-HDoHE in influenzavirus-infected mouse lung.
DISCUSSION
Novel families of biologically active lipid mediators derived from PUFA precursors have recently been uncovered and their complete stereochemical assignments established (Schwab et al., 2007; Serhan, 2007; Serhan et al., 2011; Isobe et al., 2012) . These lipid mediators include AA-derived lipoxin A4 (LXA 4 ), DHA-derived PD1 (also known neuroprotectin D1 when generated in neuronal tissues), D series resolvins (RvD1, RvD2), and the EPA-derived E series resolvins (Serhan, 2007) . These mediators are known to have anti-inflammatory properties and display potent protective actions in experimental inflammatory diseases such as peritonitis (Schwab et al., 2007; Yamada et al., 2011) and even Alzheimer's disease (Lukiw et al., 2005) . Here, we used mediator lipidomics to show the metabolic profiles and functions of these mediators in the pathology of influenza virus infection. To examine whether such bioactive mediators and biosynthetic intermediates are involved in influenza virus replication, we screened PUFA-derived products for their effects on influenza virus replication. Among them, PD1 markedly attenuated influenza virus replication and, most importantly, promoted survival of infected mice. Similar to PD1, RvD1 and RvD2 are DHA-derived products of the 12/15-LOX pathway (Serhan, 2007) . However, RvD1 and RvD2 were under the detection limit after PR8 or H5N1 virus infections, possibly because of scarce infiltration with neutrophils. The modes of interaction of NXF1 with cellular and viral RNAs are likely to be different. Constitutive transport elements (CTE) of retroviral RNAs can directly bind NXF1 (Braun et al., 1999; Grü ter et al., 1998) , and NXF1 has been shown to control ICP27-mediated export of Herpes simplex virus (HSV)-1 mRNA (Yatherajam et al., 2011) . Although influenza virus infections have been shown to downregulate the host mRNA export machinary by forming an inhibitory complex consisting of viral NS1 and the host NXF1, p15, and other mRNA export factors (Satterly et al., 2007) , it was unknown whether NXF1 is in fact involved in the virus RNA export. We show that influenza virus RNAs directly bind to NXF1 and that NXF1, in cooperating with Nup62, facilitates influenza virus RNAs export from the nucleus to the cytoplasm. However, to date it remains largely unknown the involvements of viral proteins and/or adaptor proteins in the NXF1-mediated influenza virus RNAs export (Schneider and Wolff, 2009) . Importantly, we found that PD1 attenuates the recruitment of virus RNAs to NXF1 that can bind Nup62 and suppresses the altered localization of Nup62 in the virus-infected cells. The precise mechanisms involved in this process including the PD1's interaction to viral proteins such as NS1 should be clarified in the future study. Furthermore, a yet unidentified specific receptor for PD1 would further raise the important question of how endogenous PD1 controls the downstream pathways connecting to NXF1-Nup62, although PD1 could also have many yet unexplored effects beyond regulation of the nuclear pores.
A key approach to treat severe influenza has been pharmacological targeting of both the virus life cycle and the subsequent extreme pulmonary inflammation. Current anti-influenza virus drugs are beneficial only if administered early after infection; they are much less effective if administered 48 hr after infection (Kumar, 2011) . In this context, a key finding of our study is that treatment of PD1 beginning around 48 hr after the initial infection, combined with peramivir, completely rescued mice from flu mortality, indicating that PD1 has a marked beneficial effect on severe PR8 influenza virus infections both prophylactically and, most importantly, therapeutically. Deep RNA sequencing showed that PD1 exhibits only minor effects on host poly(A) mRNA nuclear export under both noninfected as well as infected conditions, although it has not yet identified how PD1 inhibits the export specific for virus RNA rather than host RNA. Antiviral cytokine IFNb expression levels were also not affected by PD1 treatment in vivo and in vitro. These results may imply that PD1 treatment is not likely to induce a harmful inhibition of host RNA export that could possibly produce detrimental side effects in host cells. Given its demonstrated potency, its potent antiinflammatory properties in sterile and bacterial inflammation (Serhan, 2007) , and its production in healthy human airways and reduction in disease , PD1 could serve as a novel antiviral drug as well as a biomarker for severe and lethal influenza virus infections. (legend continued on next page) Animals C57BL/6 mice were bred at our animal facility. 12/15-LOX deficient mice on the C57BL/6 background were purchased from the Jackson Laboratory. Animal experiments and housing of mice were performed in accordance with institutional guidelines.
Intratracheal Influenza Virus Infection Model and Measurements of Respiratory Function
Mice were intratracheally infected with influenza viruses as described elsewhere (Ichikawa et al., 2013) . For respiratory function, airway elastance and resistance were measure as described elsewhere (Imai et al., 2005 (Imai et al., , 2008 using the flexiVent system (SCIREQ).
Mediator Lipidomics LC-MS/MS-based lipidomics analyses were performed using an highperformance liquid chromatography (HPLC) system (Waters UPLC) with a linear ion trap quadrupole mass spectrometer (QTRAP5500; AB SCIEX) equipped with an Acquity UPLC BEH C 18 column (Waters) as described (Arita, 2012) . MS/MS analyses were conducted in negative ion mode, and fatty acid metabolites were identified and quantified by multiple reaction monitoring (MRM).
Lipid Metabolites
The Protectin D1 isomer (PD1, 10S,17S-diHDoHE), RvD1, RvD2, and 15-HETE-d8, LTB 4 -d4, and PGE 2 -d4 were purchased from Cayman Chemical.
To screen for PUFA-derived compounds, we also used the Bio-active screen Lipid II Library (Cayman Chemical).
Virus Infection of Cultured Cells
The A549 human lung epithelial cells, mouse embryonic fibroblasts and MadinDarby canine kidney cells (MDCK) were washed with PBS and then infected with virus at the indicated MOIs in DMEM 0.1% BSA for 1 hr at 37 C. Cells were then washed and incubated for the indicated time periods at 37 C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS.
Immunocytochemistry A549 cells on glass coverslips were fixed with 4% paraformaldehyde and incubated with anti-NP Abs (ATCC, Hb65), anti-R309 Abs (Itoh et al., 2009 ), anti-NXF1-C Abs (Katahira et al., 1999) , or anti-Nup62 MAbs (BD Transduction Laboratories), and then incubated with appropriate secondary antibodies. Coverslips were mounted with mounting medium containing 4',6-diamidino-2-phenylindole (DAPI). Images were analyzed with a multiphoton laser microscope (A1R MP, Nikon).
Fluorescent In Situ Hybridization FISH for influenza virus RNAs and poly(A) mRNA was conducted as described previously (Amorim et al., 2007) . To generate a digoxigenin labeled positive-or negative-sense RNA probe, we linearized pSPT19-PR8-M plasmid and transcribed it in vitro with SP6 or T7 RNA polymerase, respectively, by using DIG-RNA labeling kit (Roche). A Cy3-labeled oligo (dT) probe was synthesized for poly(A) mRNA FISH. A549 cells were fixed and permeabilized. After 1 hr prehybridization, the cells were hybridized with the RNA probe for 16 hr at 37 C. A digoxigenin labeled probe was detected by indirect immunofluorescence with an antidigoxigenin fluorescein Fab fragment (Roche). Images were analyzed using multiphoton laser microscopy (A1R MP, Nikon).
Cellular Fractionation
Cytoplasmic and nuclear fractions of the cells were segregated by use of a subcellular protein fractionation kit (Thermo Scientific) in the presence of protease inhibitor cocktail (Roche) and RNase inhibitor (Toyobo).
Quantitative Real-Time PCR RNA was extracted from cells using the RNeasy Mini Kit (QIAGEN, Valencia, CA). First-strand cDNA was synthesized from DNA-free RNA using a Primescript RT reagent kit (Takara). Samples of first strand cDNA were subjected to real-time PCR quantification (Takara) using specific primers for the indicated RNAs with GAPDH or 18S as an internal control. Relative amounts of RNAs were calculated by using the comparative C T method.
RNA-Binding Protein Immunoprecipitation Assay and RIP Sequencing RIP was carried out using an immunoprecipitation kit (RIP-assay kit; MBL). Briefly, cells were homogenized and incubated overnight with protein G agarose beads (Thermo) preincubated with an anti-NXF1 Ab (BD Biosciences) or control Ab. RNAs bound to the beads were purified, and qPCR analysis was carried out. For RIP sequencing, immunoprecipitated RNAs were subjected to RNA sequencing analysis using HiSeq2000 (Illumina). The sequencing run yielded 30 million reads on average for the PD1 and vehicle treatment samples. Low-quality bases in sequencing reads were trimmed, and the trimmed reads were mapped to the influenza genome of the strain A/Puerto Rico/8/34(H1N1) by using Bowtie2 (Langmead and Salzberg, 2012) . Read counts were normalized to reads per million reads (RPM).
RNAseq
Nuclear and cytoplasmic fractionated RNAs were subjected to RNA sequencing analysis using HiSeq2000 (Illumina). The sequencing run yielded 12 million reads on average. The quality-filtered reads were aligned to the human genome hg19 by using TopHat (Trapnell et al., 2009 ). The relative expression levels (fragments per kilobase per million mapped fragments, FPKM) were calculated using cuffdiff within the software package Cufflinks version 2.0.2 (Trapnell et al., 2010) . The software package CummeRbund version 2.0.0 was used to analyze the output data of cuffdiff (Trapnell et al., 2012) .
In Vitro RNA-Binding Assay To generate PR8 M positive-sense mRNA and negative-sense vRNA, linearized pSPT19-PR8-M was in vitro transcribed with SP6 RNA polymerase and T7 RNA polymerase, respectively, by using MEGAscript kit (Ambion), followed by biotinylation using an RNA3 0 end biotinylation kit (Pierce). In vitro RNA gel shift assays were carried out using a chemiluminescent RNA electrophoretic mobility gel shift assay (EMSA) kit (Thermo Scientific) following the manufacturer's instructions. RNA-protein complexes were separated by 4% native polyacrylamide gel, electroblotted to hybond N+ membrane, and the bands visualized with streptavidin-horseradish peroxidase conjugate and chemiluminescence.
Statistical Analyses
Measurements at single time points were analyzed by using an unpaired t test or analysis of variance (ANOVA). Time courses were analyzed by repeated measurements (mixed model) of ANOVA. Log-rank tests were performed on Kaplan-Meier survival curves. All statistical tests were calculated using the GraphPad Prism 5.00 program. p < 0.05 was considered to indicate statistical significance.
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